Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | SI | P14410 | 1/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933286 | 0.84 | HSD11B1 (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21052480 | 0.84 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL232993 | 0.84 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL927785 | 0.82 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7563037 | 0.82 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11861490 | 0.82 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21299 | 0.81 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13251257 | 0.81 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15694063 | 0.81 | DGKA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL23779364 | 0.80 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647312-B1 | CRYSTAL FORM OF DEUTERATED AZD9291, PREPARATION METHOD THEREFOR, AND USE THEREOF | TYK MEDICINES INC (CN) | 2023-05-10 | — | — | EP | claimed |
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | claimed |
| EP-4583177-A1 | METHOD OF MANUFACTURING ELECTRODE, COMPOSITE ELECTRODE, ELECTROCHEMICAL ELEMENT, AND APPARATUS FOR MANUFACTURING ELECTRODE | Ricoh Company, Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| US-12173403-B2 | Group 6 transition metal-containing compositions for vapor deposition of group 6 transition metal-containing films | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) | 2024-12-24 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4362128-A1 | LIQUID COMPOSITION, METHOD FOR PRODUCING LIQUID COMPOSITION, ELECTRODE, ELECTRODE PRODUCTION APPARATUS, AND METHOD FOR PRODUCING ELECTRODE | Ricoh Company, Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-5936132-A | Alkene intermediates and synthesis thereof | MATSUMOTO MASAKATSU (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5698727-A | 1,2-dioxetane derivatives, intermediates for syntheses thereof and methods of producing the intermediates | MATSUMOTO MASAKATSU (JP) | 1997-12-16 | — | — | US | disclosed |
| US-5650525-A | 1,2-dioxetane derivatives, intermediates for syntheses thereof and methods of producing the intermediates | TOSOH CORPORATION (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0671395-A1 | 1,2-Dioxetane derivatives, intermediates for syntheses thereof and methods of producing the intermediates | Matsumoto, Masakatsu (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0605686-A1 | EMULSION POLYMERS FOR USE IN HAIR FIXATIVES | National Starch and Chemical Investment Holding Corporation (US) | 1994-07-13 | — | — | EP | disclosed |
| CN-1078475-A | A kind of improved with the steroid 3-halogen-3 that replaces, the 5-diene derivatives is converted into the steroid 3 of replacement, the method for 5-diene-3-carboxylic acid derivative and used intermediate | SMITHKLINE BEECHAM CORP (US) | 1993-11-17 | — | — | CN | disclosed |
| US-5011947-A | Enzyme inhibitors for cholesterol biosythesis | BRISTOL-MYERS (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0295839-A2 | Pyrimidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | GAA 313/4885MGAM 1584/4885SI 2362/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | GAA 4203/4885MGAM 4724/4885SI 756/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | GAA 1769/4885MGAM 3635/4885SI 3410/4885 |
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | VIP, GRPR, ITCH | GAA 3565/4885MGAM 2815/4885SI 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.